Zacks Investment Research on MSN

NTRA's Signatera secures PMDA approval for MRD testing in CRC in Japan

Natera NTRA recently announced that Signatera has received PMDA approval in Japan for use in colorectal cancer (CRC) patients ...
Business Wire

Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular ...

Natera secures landmark Japan nod for Signatera in colorectal cancer

Natera Inc. NTRA said Japan’s Ministry of Health, Labour and Welfare approved its Signatera molecular residual disease (MRD) ...

Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has ...

NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice ...
Business Wire

Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap ...
Nasdaq

New Study Validates the Signatera® MRD Test and Demonstrates its Clinical Utility in Early-Stage Esophageal Cancer

AUSTIN, Texas, July 28, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new peer-reviewed paper published in Gastroenterology ...
Yahoo

Natera’s Solomon Moshkevich on how MRD testing pinpoints cancer recurrence

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive ...
Nasdaq

FDA Grants Breakthrough Device Designation to Natera's Signatera Test

SAN CARLOS, Calif., May 6, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced that the U.S. Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its ...
Business Insider

Medicare Issues Draft Local Coverage Determination for Signatera™ in Immunotherapy Response Monitoring

SAN CARLOS, Calif., Sept. 24, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the CMS Molecular Diagnostics Program (MOLDX) ...
Business Insider

New Results From the Landmark Prospective CIRCULATE Trial Expand Clinical Utility of the Signatera® MRD Test in Colorectal Cancer

AUSTIN, Texas, July 2, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and ...
Seeking Alpha

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...